Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
JUNS
Upturn stock ratingUpturn stock rating

Jupiter Neurosciences, Inc. Common Stock (JUNS)

Upturn stock ratingUpturn stock rating
$1.34
Last Close (24-hour delay)
Profit since last BUY57.65%
upturn advisory
WEAK BUY
BUY since 51 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: JUNS (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

0 Analysts rated it

Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.

Analysis of Past Performance

Type Stock
Historic Profit 57.65%
Avg. Invested days 51
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 200.22M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 0.51 - 19.51
Updated Date 05/11/2025
52 Weeks Range 0.51 - 19.51
Updated Date 05/11/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 202546214
Price to Sales(TTM) -
Enterprise Value 202546214
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 31000000
Shares Floating -
Shares Outstanding 31000000
Shares Floating -
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Jupiter Neurosciences, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Jupiter Neurosciences, Inc. is a pharmaceutical company focused on the development of therapies for neurological diseases. Founded in 2015, it has been focused on developing a new treatment for Mucopolysaccharidosis Type III (MPS III), also known as Sanfilippo syndrome, and other neurological conditions.

business area logo Core Business Areas

  • Neurological Disease Therapies: Development of therapeutics for neurological diseases, focusing on MPS III and other indications.

leadership logo Leadership and Structure

The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure is typical of a biotech firm, with departments dedicated to research, development, clinical trials, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • JOTROLu2122: JOTROLu2122 is Jupiter Neurosciencesu2019 product candidate under development for the potential treatment of Mucopolysaccharidosis Type III (MPS III) (Sanfilippo syndrome). No market share is established yet as the product is still under development. Competitors would be gene therapy approaches such as those from Lysogene, although JOTROL targets neuroinflammation rather than directly addressing the genetic defect.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry focused on neurological diseases is characterized by high unmet needs, significant research and development investment, and a complex regulatory landscape. There is increasing focus on rare diseases, as well as more common neurological conditions.

Positioning

Jupiter Neurosciences is positioned as a company specializing in neurological diseases, with a focus on repurposing drugs to make therapeutics for a new indication. Its competitive advantage lies in its drug development strategy and specific target indications.

Total Addressable Market (TAM)

The TAM for neurological disease therapies is substantial and expected to grow, reaching billions of dollars annually. Jupiter Neurosciences is positioned to capture a portion of this market with their MPS III product and future products, should they be approved. Precise TAM estimates depend on the specific diseases targeted.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach
  • Focus on unmet medical needs
  • Experienced management team
  • Existing drugs may already have certain FDA approvals, allowing for a faster route to approval

Weaknesses

  • Limited financial resources
  • Dependence on a few key pipeline products
  • Clinical trial risks
  • Regulatory hurdles

Opportunities

  • Partnerships and collaborations
  • Expansion into new therapeutic areas
  • Fast track regulatory pathways
  • Orphan drug designation benefits

Threats

  • Competition from larger pharmaceutical companies
  • Clinical trial failures
  • Regulatory setbacks
  • Intellectual property challenges

Competitors and Market Share

competitor logo Key Competitors

  • LLY (Eli Lilly and Company)
  • BMY (Bristol-Myers Squibb)
  • Lysogene (Currently not traded on a major US exchange but is a competitor)

Competitive Landscape

Jupiter Neurosciences faces competition from larger pharmaceutical companies with established pipelines and resources. Its competitive advantage lies in its focus on neurological diseases and a particular therapeutic approach, as well as its speed to market.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is tied to pipeline advancement and clinical trial progress.

Future Projections: Future growth depends on successful clinical trials and regulatory approvals.

Recent Initiatives: Recent initiatives would include the ongoing clinical trial of JOTROLu2122.

Summary

Jupiter Neurosciences is an early-stage pharmaceutical company targeting neurological diseases. The company's success is contingent on the clinical trial results and regulatory approval of its primary drug candidate. It faces significant competition from larger companies with deeper resources. Its focused approach and novel strategy offer potential upside, but the company is highly speculative and carries substantial risk.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • ClinicalTrials.gov
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. The information provided is based on publicly available data, which may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Jupiter Neurosciences, Inc. Common Stock

Exchange NASDAQ
Headquaters Jupiter, FL, United States
IPO Launch date 2024-12-03
Co-Founder, CEO & Chairman of the Board Mr. Christer Rosen
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.